Barclays PLC Increases Stock Holdings in RadNet, Inc. (NASDAQ:RDNT)

Barclays PLC boosted its stake in RadNet, Inc. (NASDAQ:RDNT - Free Report) by 7.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 125,570 shares of the medical research company's stock after purchasing an additional 8,592 shares during the period. Barclays PLC owned about 0.17% of RadNet worth $8,770,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. USA Financial Formulas acquired a new stake in shares of RadNet in the fourth quarter valued at about $30,000. Fifth Third Bancorp raised its position in shares of RadNet by 84.3% in the 4th quarter. Fifth Third Bancorp now owns 667 shares of the medical research company's stock worth $47,000 after acquiring an additional 305 shares in the last quarter. Smartleaf Asset Management LLC lifted its stake in RadNet by 377.0% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,345 shares of the medical research company's stock valued at $96,000 after buying an additional 1,063 shares during the period. Twin Tree Management LP bought a new position in RadNet during the fourth quarter worth $106,000. Finally, IFP Advisors Inc boosted its position in shares of RadNet by 39.1% during the 4th quarter. IFP Advisors Inc now owns 1,697 shares of the medical research company's stock worth $119,000 after purchasing an additional 477 shares in the last quarter. 77.90% of the stock is owned by institutional investors.

Insider Transactions at RadNet

In other news, CEO Cornelis Wesdorp sold 1,000 shares of RadNet stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $50.52, for a total value of $50,520.00. Following the transaction, the chief executive officer now owns 55,995 shares in the company, valued at approximately $2,828,867.40. The trade was a 1.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director David L. Swartz sold 25,000 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $50.84, for a total value of $1,271,000.00. Following the completion of the sale, the director now owns 174,067 shares of the company's stock, valued at $8,849,566.28. The trade was a 12.56 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,000 shares of company stock worth $1,926,730. 5.12% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

RDNT has been the topic of several research reports. Jefferies Financial Group lowered their price objective on shares of RadNet from $100.00 to $80.00 and set a "buy" rating on the stock in a report on Wednesday, January 15th. StockNews.com upgraded shares of RadNet to a "sell" rating in a research note on Wednesday, March 19th. Barclays dropped their price target on shares of RadNet from $74.00 to $60.00 and set an "overweight" rating on the stock in a research report on Monday, March 24th. Raymond James upgraded shares of RadNet from an "outperform" rating to a "strong-buy" rating and cut their price target for the stock from $85.00 to $65.00 in a report on Wednesday, March 5th. Finally, Truist Financial decreased their price objective on shares of RadNet from $88.00 to $74.00 and set a "buy" rating for the company in a research note on Friday, April 11th. One analyst has rated the stock with a sell rating, three have given a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and an average price target of $69.75.

RadNet Price Performance

RDNT stock traded down $0.19 during midday trading on Friday, reaching $50.26. The company had a trading volume of 581,287 shares, compared to its average volume of 664,913. The firm has a 50-day moving average price of $51.71 and a 200-day moving average price of $64.42. The company has a debt-to-equity ratio of 0.89, a current ratio of 2.16 and a quick ratio of 2.16. The company has a market capitalization of $3.72 billion, a P/E ratio of -717.90 and a beta of 1.59. RadNet, Inc. has a 1 year low of $45.00 and a 1 year high of $93.65.

RadNet (NASDAQ:RDNT - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical research company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01. The firm had revenue of $477.10 million for the quarter, compared to analyst estimates of $459.42 million. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. On average, research analysts anticipate that RadNet, Inc. will post 0.56 earnings per share for the current fiscal year.

RadNet Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.